A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)

Stopped Based on the data and observed benefit-risk profile, the trial's independent oversight committee recommended that enrollment not resume.

Conditions

• Cerebrovascular Accident
• Brain Ischemia
• Acute Disease

Interventions

• DRUG: Abciximab

Sponsor

Centocor, Inc.

Collaborators

• [object Object]